The proportion and phenotypic changes of CD4+CD25−Foxp3+ T cells in patients with untreated rheumatoid arthritis

BMC Immunology

Table 3 Cytokines analysis of CD4⁺CD25⁻Foxp3⁺ T cells and CD4⁺CD25⁺Foxp3⁺ Treg cells

Cytokines	HCs	RA	p value (HCs vs RA)
IL-10%/CD4⁺CD25⁻Foxp3⁺ T cells	28.33 (15.20–36.53)	29.43 (18.72–43.84)	0.651
IL-10%/CD4⁺CD25⁺Foxp3⁺ Treg cells	21.69 (16.48–28.50)	20.36 (13.34–33.86)	0.778
IL-10%/CD4⁺CD25⁺Foxp3⁻ effector T cells	21.25 (15.22–29.93)	15.24 (11.20–25.51)	0.254
IL-17A% /CD4⁺CD25⁻Foxp3⁺ T cells	3.20 (1.85–5.51)†	6.19 (3.94–8.12)	0.048
IL-17A%/CD4⁺CD25⁺Foxp3⁺ Treg cells	2.62 (1.58–5.36)	6.18 (5.03–13.34)	0.009
IL-17A% /CD4⁺CD25⁺Foxp3⁻ effector T cells	14.98 (8.58–19.07)	7.76 (5.27–20.07)	0.334
IFN-γ %/CD4⁺CD25⁻Foxp3⁺ T cells	9.87 (4.61–11.20)*†	10.34 (5.96–16.54)*†	0.651
IFN-γ%/CD4⁺CD25⁺Foxp3⁺ Treg cells	2.96 (1.57–4.28)	3.72 (2.73–5.73)	0.395
IFN-γ%/CD4⁺CD25⁺Foxp3⁻ effector T cells	3.62 (3.54–4.32)	6.83 (3.44–12.66)	0.279

All the data were demonstrated as median [IQR, 25th-75th percentile]
HCs, healthy controls; RA, rheumatoid arthritis; IL-10, interleukin 10; IL17-A, interleukin 17A; IFN-γ, interferon gamma
*Indicates significance (p < 0.05) compared with CD4⁺CD25 ⁺Foxp3⁺ Treg cells in RA group or HCs
^†Indicates significance (p < 0.05) compared with CD4⁺CD25⁺Foxp3⁻ effector T cells in RA group or HCs

ISSN: 1471-2172